Please assess the completion status of the following clinical trial:

Trial Title: Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with RA in accordance with the 1987 classification criteria of ACR~* Aged 20 to 75 years inclusive at enrolment (within 2 weeks before starting treatment with the investigational drug)~* Treated with MTX at ≥6 mg/week for at least 8 weeks immediately before enrolment~* Rheumatoid arthritis of duration ≤10 years~* DAS28-ESR ≥3.2 (within 2 weeks before starting treatment with the investigational drug)~* Having received and thoroughly understood an adequate explanation about participation in the study, patients who have personally and voluntarily provided written informed consent~Major exclusion criteria:~* Patients who were Steinbrocker Class IV.~* Patients who received leflunomide within 12 weeks, DMARDs other than MTX within 8 weeks , or tacrolimus within 4 weeks before the 1st TCZ infusion.~* Patients who previously received biologic DMARDs including TCZ.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SWITCH (Type: ACTIVE_COMPARATOR): Tocilizumab monotherapy
- ADD-ON (Type: ACTIVE_COMPARATOR): Tocilizumab plus methotrexate combination

Based on this trial design, predict the completion outcome and termination type (if applicable).